| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S2210-7401(12)70016-5 |
| P698 | PubMed publication ID | 23141888 |
| P2093 | author name string | Christophe Corpechot | |
| P2860 | cites work | Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression | Q24336351 |
| Chronic diarrhea due to excessive bile acid synthesis and not defective ileal transport: a new syndrome of defective fibroblast growth factor 19 release | Q24603434 | ||
| A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group | Q28243457 | ||
| Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis | Q33745849 | ||
| Trends in liver transplantation for primary biliary cirrhosis in the Netherlands 1988-2008. | Q33776154 | ||
| 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. | Q34143282 | ||
| Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited | Q34146325 | ||
| Effect of ursodeoxycholic acid treatment on ileal absorption of bile acids in man as determined by the SeHCAT test | Q34394412 | ||
| Characterisation of patients with a complete biochemical response to ursodeoxycholic acid | Q34408204 | ||
| Survival in ursodeoxycholic acid-treated patients with biliary cirrhosis | Q71832756 | ||
| Ursodeoxycholic acid in the treatment of primary biliary cirrhosis | Q72401649 | ||
| Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial | Q73026352 | ||
| Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis | Q74529900 | ||
| Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy | Q77058192 | ||
| Relationship between biliary and serum bile acids and response to ursodeoxycholic acid in patients with primary biliary cirrhosis | Q77225890 | ||
| A randomized trial in primary biliary cirrhosis comparing ursodeoxycholic acid in daily doses of either 10 mg/kg or 20 mg/kg. Dutch Multicentre PBC Study Group | Q77499263 | ||
| Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group | Q77807948 | ||
| Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial | Q77872001 | ||
| Assessment of biliary bicarbonate secretion in humans by positron emission tomography | Q77921993 | ||
| Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health | Q83637970 | ||
| Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome | Q84441124 | ||
| American Association for the Study of Liver Diseases endpoints conference: design and endpoints for clinical trials in primary biliary cirrhosis | Q84476629 | ||
| Serum bilirubin: a prognostic factor in primary biliary cirrhosis | Q34494336 | ||
| Systematic review: ursodeoxycholic acid--adverse effects and drug interactions | Q35583064 | ||
| Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses | Q36801651 | ||
| Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO⁻₃ output | Q37096585 | ||
| A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation | Q37383640 | ||
| Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis | Q37760788 | ||
| Biochemical response to ursodeoxycholic acid predicts long-term outcome in Japanese patients with primary biliary cirrhosis | Q37855976 | ||
| Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action | Q38058981 | ||
| Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid | Q39293482 | ||
| Suppressive effect of ursodeoxycholic acid on type IIA phospholipase A2 expression in HepG2 cells | Q40442161 | ||
| The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis | Q40737262 | ||
| Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis | Q40883127 | ||
| Transplantation trends in primary biliary cirrhosis. | Q42632785 | ||
| UDCA, PBC, and biochemistry, what does normal mean? | Q43086212 | ||
| Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone | Q43086793 | ||
| Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid | Q43483632 | ||
| Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center | Q43513105 | ||
| Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid | Q43893454 | ||
| Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients | Q43903202 | ||
| Improved liver tests and greater biliary enrichment with high dose ursodeoxycholic acid in early stage primary biliary cirrhosis | Q44139912 | ||
| Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis | Q44487597 | ||
| Treatment with ursodeoxycholic acid is associated with weight gain in patients with primary biliary cirrhosis | Q44517790 | ||
| Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients | Q44617739 | ||
| Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis | Q44966935 | ||
| Survival of anti-mitochondrial antibody-positive and -negative primary biliary cirrhosis patients on ursodeoxycholic acid treatment | Q45074381 | ||
| The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis | Q45134599 | ||
| The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis | Q45247238 | ||
| Pregnancy in women with ursodeoxycholic acid-treated primary biliary cirrhosis | Q45264417 | ||
| Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial | Q45309693 | ||
| Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid | Q46126105 | ||
| Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis | Q46408092 | ||
| Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis | Q46568191 | ||
| The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: A prospective, multicenter study | Q46614923 | ||
| Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies | Q46728239 | ||
| 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice | Q46939923 | ||
| Geotherapeutics of primary biliary cirrhosis: bright and sunny around the Mediterranean but still cloudy and foggy in the United Kingdom | Q46982754 | ||
| Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid | Q51636366 | ||
| Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: a population-based cohort study. | Q55044287 | ||
| EASL Clinical Practice Guidelines: management of cholestatic liver diseases. | Q55051951 | ||
| Primary biliary cirrhosis | Q56428273 | ||
| The long-term effect of ursodeoxycholic acid on laboratory liver parameters in biochemically non-advanced primary biliary cirrhosis | Q58376655 | ||
| Effect of chronic administration of ursodeoxycholic acid on the ileal absorption of endogenous bile acids in man | Q68583675 | ||
| Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid | Q68925952 | ||
| Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial | Q69357047 | ||
| Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? | Q69896715 | ||
| Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy | Q70670255 | ||
| Time course of histological progression in primary biliary cirrhosis | Q70869710 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | primary biliary cholangitis | Q1072420 |
| P304 | page(s) | S13-20 | |
| P577 | publication date | 2012-09-01 | |
| P1433 | published in | Clinics and research in hepatology and gastroenterology | Q26853950 |
| P1476 | title | Primary biliary cirrhosis and bile acids | |
| P478 | volume | 36 Suppl 1 |
| Q36389501 | Circulating FGF19 closely correlates with bile acid synthesis and cholestasis in patients with primary biliary cirrhosis |
| Q92886852 | Emerging roles of bile acids in mucosal immunity and inflammation |
| Q90095854 | Fenofibrate-induced hepatotoxicity: A case with a special feature that is different from those in the LiverTox database |
| Q39584105 | Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score |
| Q35644328 | Metal Zn(II), Cu(II), Ni (II) complexes of ursodeoxycholic acid as putative anticancer agents |
| Q26748613 | Novel bile acid therapeutics for the treatment of chronic liver diseases |
| Q38175055 | Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis |
| Q38911238 | Obeticholic acid for the treatment of primary biliary cholangitis |
| Q26799419 | Primary biliary cirrhosis: From bench to bedside |
| Q53479325 | Protective Effects of Alisol B 23-Acetate Via Farnesoid X Receptor-Mediated Regulation of Transporters and Enzymes in Estrogen-Induced Cholestatic Liver Injury in Mice. |
| Q38974002 | Reversal of liver cirrhosis: current evidence and expectations |
| Q38174167 | Review article: controversies in the management of primary biliary cirrhosis and primary sclerosing cholangitis |
| Q38265728 | Role of farnesoid X receptor in inflammation and resolution. |
| Q35942610 | The Cholangiopathies |
Search more.